ESMO members: The 2nd edition of the Essentials for Clinicians is available to download!
All resources: Abstracts are open access, presentations and webcasts are reserved to ESMO members
Haven't had much time lately? Here's what you may have missed in the last few weeks.
Sign-up to receive the OncologyPRO alert
every 2 weeks.
New! e-Update on Gastric Cancer Treatment Recommendations
Find all the latest ESMO Guidelines
and
discover the ESMO Guidelines Slide Sets
!
For full access to all OncologyPRO content: daily medwireNews, ESMO books, slides and webcasts... and much more.
Become an ESMO member today!
24 May 2019
Adding hydroxychloroquine to chemotherapy did not significantly improve overall survival in patients with metastatic pancreatic ductal adenocarcinoma
23 May 2019
Chinese small-cell lung cancer patients given once-daily thoracic radiotherapy have a reduced risk of distant disease to the brain compared with those...
22 May 2019
Adding atezolizumab to platinum-based chemotherapy extends overall survival for patients with stage IV nonsquamous, non-small-cell lung cancer without...
21 May 2019
Patients undergoing adjuvant combination chemotherapy for stage III colon cancer derive no additional survival benefit from 6 months versus 3 months...
20 May 2019
The increasing use of waterfall plots in oncology clinical trial reports may visually overestimate the response rate
In non-squamous advanced NSCLC, 5 biomarkers should be tested in the initial biopsy to base the first line treatment decision: EGFR, ALK, ROS-1, BRAF and PD-L1.When it hasn't been done at baseline, Solange Peters says it is still important to search for these biomarkers to make a treatment decision after progression.
When an initial biopsy results are available, at progression it is not mandatory to re-test. However, in case more targeted therapies are available at the clinic or for clinical research purposes if rare mutations are found, the second biopsy may give valuable information to decide on a second or third line treatment, especially when an oncogenic driver has been identified at baseline.
10-11 May 2019, Zurich, Switzerland
02-04 May 2019, Berlin, Germany
26-27 Apr 2019, Lugano, Switzerland
13-14 Apr 2019, Hong Kong
12-13 Apr 2019, Prague, Czech Republic
12-17 Apr 2019, Sibenik, Croatia
10-13 Apr 2019, Geneva, Switzerland
03-07 Apr 2019, Lima, Peru
24-28 Mar 2019, Berlin, Germany
22-24 Mar 2019, Sao Paulo, Brazil
14-16 Mar 2019, Barcelona, Spain
06-08 Mar 2019, Manchester, United Kingdom
25-27 Feb 2019, Paris, France
22-22 Feb 2019, Valencia, Spain
15-17 Feb 2019, Cape Town, South Africa
